A detailed history of Tower Research Capital LLC (Trc) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,364 shares of TRDA stock, worth $111,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,364
Previous 2,880 120.97%
Holding current value
$111,751
Previous $41,000 146.34%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.65 - $17.86 $47,556 - $62,224
3,484 Added 120.97%
6,364 $101,000
Q2 2024

Aug 13, 2024

BUY
$11.85 - $16.45 $28,973 - $40,220
2,445 Added 562.07%
2,880 $41,000
Q1 2024

May 15, 2024

SELL
$11.58 - $17.0 $61,895 - $90,865
-5,345 Reduced 92.47%
435 $6,000
Q4 2023

Feb 13, 2024

BUY
$11.36 - $16.99 $54,266 - $81,161
4,777 Added 476.27%
5,780 $87,000
Q3 2023

Nov 14, 2023

BUY
$13.61 - $18.01 $5,566 - $7,366
409 Added 68.86%
1,003 $15,000
Q2 2023

Aug 14, 2023

SELL
$11.02 - $18.01 $7,691 - $12,570
-698 Reduced 54.02%
594 $8,000
Q1 2023

May 09, 2023

BUY
$9.58 - $16.2 $8,095 - $13,689
845 Added 189.04%
1,292 $19,000
Q4 2022

Feb 10, 2023

SELL
$13.52 - $22.89 $27,864 - $47,176
-2,061 Reduced 82.18%
447 $6,000
Q3 2022

Nov 10, 2022

BUY
$9.65 - $15.76 $24,202 - $39,526
2,508 New
2,508 $40,000
Q2 2022

Aug 15, 2022

SELL
$5.49 - $12.94 $13,642 - $32,155
-2,485 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$7.99 - $16.93 $55 - $118
7 Added 0.28%
2,485 $23,000
Q4 2021

Feb 14, 2022

BUY
$13.7 - $35.0 $33,948 - $86,730
2,478 New
2,478 $42,000

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $551M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.